RT Journal Article
SR Electronic
T1 SIENNA: Lightweight Generalizable Machine Learning Platform for Brain Tumor Diagnostics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.03.24305210
DO 10.1101/2024.04.03.24305210
A1 Sunil, Sreya
A1 Rajeev, Rahul S.
A1 Chatterjee, Ayan
A1 Pilitsis, Julie
A1 Mukherjee, Amitava
A1 Paluh, Janet L.
YR 2024
UL http://medrxiv.org/content/early/2024/04/04/2024.04.03.24305210.abstract
AB The transformative integration of Machine Learning (ML) for Artificial General Intelligence (AGI)-enhanced clinical imaging diagnostics, is itself in development. In brain tumor pathologies, magnetic resonance imaging (MRI) is a critical step that impacts the decision for invasive surgery, yet expert MRI tumor typing is inconsistent and misdiagnosis can reach levels as high as 85%. Current state-of-the-art (SOTA) ML brain tumor models struggle with data overfitting and susceptibility to shortcut learning, further exacerbated in large-sized models with many tunable parameters. In a comparison with multiple SOTA models, our deep ML brain tumor diagnostics model, SIENNA, surpassed limitations in four key areas of prioritized minimal data preprocessing, an optimized architecture that reduces shortcut learning and overfitting, integrated inductive cross-validation method for generalizability, and smaller neural architecture. SIENNA is applicable across MRI machines and 1.5 and 3.0 Tesla, and achieves high average accuracies on clinical DICOM MRI data across three-way classification: 92% (non-tumor), 91% (GBM), and 93% (MET) with retained high F1 and AUROC values for limited false positives/negatives. SIENNA is a lightweight clinical-ready AGI framework compatible with future multimodal expanded data integration.Competing Interest StatementSIENNA is patent pending in 63,465,719, an Artificial Intelligence System for Tumor Diagnostics of Clinical MRI Datasets. JLP, AM and AC are cofounders of the startup ITrakNeuro Inc. Dr. Pilitsis receives grant support from Medtronic, Boston Scientific, Abbott, NIH 2R01CA166379, NIH R01EB030324, and NIH U44NS115111. She is the medical advisor for Aim Medical Robotics and has stock equity.Funding StatementSIENNA analysis is supported by the State University of New York Research Foundation Technology Accelerator Fund (TAF) award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of SUNY Polytechnic Institute, SUNY Albany gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and the code is available on our GitHub repository. https://github.com/ITrakNeuro/SIENNA-Nature.git